Bristol Gets First Mover-Advantage, Again, With Opdivo Kidney Cancer Approval
This article was originally published in The Pink Sheet Daily
FDA’s breakthrough approval of Opdivo in second-line metastatic renal cell carcinoma comes on Nov. 23, just one week after filing was accepted.
You may also be interested in...
During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.